GlassScriptPhysician profile
Lenise A Banse
NPI 1427102466
$422.36
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.59 · 2020: $31.37 · 2021: $180 · 2022: $175.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $65.83 | 2021-2022 | |
| Janssen Biotech, INC. | $58.01 | 2021-2022 | |
| Epi Health, LLC | $57.93 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $47.21 | 2020-2021 | |
| Lilly USA, LLC | $41.63 | 2021-2022 | |
| Genzyme Corporation | $39.27 | 2021-2022 | |
| Pfizer INC. | $38.98 | 2020-2021 | |
| Galderma Laboratories, L.P. | $36.59 | 2019 | |
| Leo Pharma INC. | $18.89 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.02 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenise Banse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.